Baricitinib is under clinical development by Eli Lilly and Co and currently in Phase II for Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease). According to GlobalData, Phase II drugs for Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease) have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Baricitinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Baricitinib (Olumiant) is an anti-inflammatory, immunomodulating and antineoplastic agent. It is formulated as film-coated tablets for oral route of administration. Baricitinib is indicated for the treatment of rheumatoid arthritis (RA) (including the prevention of structural injury of joints) in patients with inadequate response to standard-of-care therapies. Baricitinib in combination with remdesivir is indicated for the treatment of suspected or laboratory confirmed coronavirus disease 2019 (COVID-19) in certain hospitalized adults and pediatric patients 2 years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Olumiant is indicated as a first-in-disease systemic treatment for adults with severe alopecia areata.
Baricitinib is under development for the treatment of active primary Sjogren’s syndrome, atopic dermatitis, polymyalgia rheumatic, mild cognitive impairment, Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), giant cell arteritis, chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), stimulator of interferon genes (STING) associated vasculopathy with onset during infancy (SAVI), chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE), Nakajo-Nishimura Syndrome, Aicardi-Goutieres Syndrome (AGS), severe juvenile dermatomyositis (JDM), focal segmental glomerulosclerosis (FSGS), Human Immunodeficiency Virus (HIV) Infections (AIDS), long COVID and non-diabetic APOL1-associated chronic kidney disease due to hypertension (HTN-CKD). It acts by targeting JAK1 and JAK2. It was also under development for primary biliary cholangitis, juvenile idiopathic arthritis-associated anterior uveitis, diabetic nephropathy, psoriatic arthritis and moderate-to-severe chronic plaque psoriasis, systemic lupus erythematosus, auto inflammatory syndromes including Aicardi Goutieres syndrome.
Eli Lilly and Co overview
Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, immune disorders, men’s health, and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, South Asia, the Middle East, Africa, and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.
For a complete picture of Baricitinib’s drug-specific PTSR and LoA scores, buy the report here.